Xi'an Mokemei Biotechnology: difference between revisions
Diff·revision 29 → 30·07:17, 28 Jul 2025
Difference between revision 29 and revision 30 of Xi'an Mokemei Biotechnology. 3 lines changed; the page grew by 609 bytes.
| Revision 29 — 12:03, 22 Jul 2025 BlankVialBo (talk) split overlong sentence 6,944 bytes ±0 | Revision 30 — 07:17, 28 Jul 2025 VerifyVesna (talk) move unsourced paragraph to talk 7,553 bytes +609 | ||
|---|---|---|---|
| 19 | }} | 19 | }} |
| 20 | {{hatnote|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}} | 20 | {{hatnote|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}} |
| + | 21 | {{primarysources|date=July 2026|talk=How should the lot-mismatch reports be presented?}} | |
| 21 | 22 | ||
| 22 | '''Xi'an Mokemei Biotechnology Co., Ltd.''' (trading as '''MKM'''; mokemeibiotechnology.com) is a research-compound supplier trading as MKM from Xi'an, Shaanxi, China, incorporated in 2016, distributing research peptides, SARMs and raw materials with batch documentation.{{r|registry,selfpub}} | 23 | '''Xi'an Mokemei Biotechnology Co., Ltd.''' (trading as '''MKM'''; mokemeibiotechnology.com) is a research-compound supplier trading as MKM from Xi'an, Shaanxi, China, incorporated in 2016, distributing research peptides, SARMs and raw materials with batch documentation.{{r|registry,selfpub}} |
| ⋮ | ⋮ | ||
| 51 | == Independent testing record == | 52 | == Independent testing record == |
| 52 | Submitted reports on MKM material to July 2026 cover the incretin range and a small number of repair peptides. Reported [[Area percent purity|area percent]] figures have been high in most cases, with two reports in the set falling below the accompanying certificate by more than a percentage point.{{r|reports}} | 53 | Submitted reports on MKM material to July 2026 cover the incretin range and a small number of repair peptides. Reported [[Area percent purity|area percent]] figures have been high in most cases, with two reports in the set falling below the accompanying certificate by more than a percentage point.{{r|reports}} |
| + | 54 | ||
| + | 55 | A discrepancy of that size between an independent report and a certificate has several innocent explanations — different columns, different integration parameters, different [[Reference standard|reference standards]], sample handling between purchase and testing — and does not establish that either figure was wrong. It is recorded because [[Purity claim inflation|inflated purity claims]] are a documented failure mode in this sector and a discrepancy is the only observable that would indicate one.{{r|reports}} | |
| 53 | 56 | ||
| 54 | == References == | 57 | == References == |